Merck and Eisai reveal late-stage fail for Keytruda and Lenvima in gastroesophageal cancer

The combination of Merck’s Keytruda and Eisai’s Lenvima failed to prolong patients’ lives versus the comparator in another cancer study, but the companies say they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

America’s health system isn’t ready for the surge of seniors with disabilities

The number of older adults with disabilities — difficulty with walking, seeing, hearing, memory, cognition, or performing daily tasks such as bathing or using the

January 17, 2024

Early treatment with convalescent plasma may reduce risk of long COVID

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19

September 20, 2023

Hims & Hers Launches AI Service to Help Providers Personalize Treatments

[embedded content] What You Should Know: – Hims & Hers Health, the leading health and wellness platform, has unveiled MedMatch, an AI-powered solution designed to

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.